JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB81280

Anti-Integrin alpha 4/CD49D antibody [EPR1355Y]

  • 20ul selling size
  • RabMAb
  • Recombinant
  • KO Validated
  • What is this?

Be the first to review this product! Submit a review

|

(17 Publications )

Rabbit Recombinant Monoclonal Integrin alpha 4/CD49D antibody. Suitable for WB and reacts with Human samples. Cited in 17 publications.
4 Images
Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)
  • WB

Unknown

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)

All lanes:

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (ab81280) at 1/2000 dilution

All lanes:

Jurkat cell lysate at 10 µg

Secondary

All lanes:

HRP labelled goat anti rabbit at 1/2000 dilution

Predicted band size: 114 kDa

Observed band size: 150 kDa

false

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)
  • WB

Lab

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)

Lane 1 : Integrin alpha 4 knockout HAP1 cell lysate (20 μg)

Lane 2 : Wild-type HAP1 cell lysate (20 μg)

Lanes 1 and 2 : Merged signal (red and green). Green - ab81280 observed at 150 kDa. Red - loading control, ab8226, observed at 42 kDa.

ab81280 was shown to recognize Integrin alpha 4 in wild-type HAP1 cells along with additional cross-reactive bands. No bands were observed when Integrin alpha 4 knockout samples were used. Wild-type and Integrin alpha 4 knockout samples were subjected to SDS-PAGE. ab81280 and ab8226 (loading control to beta actin) were diluted 1/2000 and 1/1000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1hr at room temperature before imaging.

All lanes:

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (ab81280)

Predicted band size: 114 kDa

false

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)
  • WB

Lab

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)

Lanes 1 - 2 : Merged signal (red and green). Green - ab81280 observed at 150 kDa. Red - loading control, ab8245, observed at 37 kDa.

This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using Licor blocking buffer before being incubated with ab81280 and ab8245 (loading control) overnight at 4°C. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at a 1 : 10000 dilution for 1hr at room temperature and then imaged.

All lanes:

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (ab81280) at 1/1000 dilution

Lane 1:

Jurkat whole cell lysate at 20 µg

Lane 2:

Mouse spleen tissue lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 114 kDa

Observed band size: 150 kDa

false

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)
  • WB

CiteAb

Western blot - Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] (AB81280)

Integrin alpha 4/CD49D western blot using anti-Integrin alpha 4/CD49D antibody [EPR1355Y] ab81280. Publication image and figure legend from Yan, J., Yang, X., et al., 2020, J Cell Mol Med, PubMed 31680442.

ab81280 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab81280 please see the product overview.

CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma. (A,B) Protein expression of ITGA4 in GTM3, GTM3 + CD9 and GTM3 + pcDNA3.1 groups. n = 6. (A,C) Protein expression of p-PI3K in GTM3, GTM3 + CD9 and GTM3 + pcDNA3.1 groups. n = 6. (A,D) Protein expression of p-Akt in GTM3, GTM3 + CD9 and GTM3 + pcDNA3.1 groups. n = 6. (A,E) Protein expression of clevage caspase3 in GTM3, GTM3 + CD9 and GTM3 + pcDNA3.1 groups. n = 6. *P < .05 vs iHTM group, #P < .05 vs GTM3 group. (F-G) FCAS results of cells from iHTM, GTM3, GTM3 + CD9 and GTM3 + pcDNA3.1 groups. n = 3. *P < .05 vs iHTM group, #P < .05 vs GTM3 group

false

  • Carrier free

    Anti-Integrin alpha 4/CD49D antibody [EPR1355Y] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR1355Y

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/2000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please contact us for more information.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Conditional Ambient
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Integrin alpha 4 also known as CD49D or ITGA4 is a transmembrane receptor with a mass of approximately 150 kDa. This protein is expressed on the surface of leukocytes including T and B lymphocytes monocytes and eosinophils. Integrin alpha 4 functions by interacting mechanically with the extracellular matrix components and endothelial cell counter-receptors like VCAM-1 facilitating cell adhesion and migration. Its expression is vital for the immune cells' ability to move and locate sites of inflammation or injury.
Biological function summary

Integrin alpha 4 forms a heterodimer complex with beta subunits like beta 1 (forming VLA-4) or beta 7 allowing it to mediate adhesion and signaling pathways. In particular the alpha 4 and beta 1 dimerization gives rise to a high-affinity receptor for fibronectin and VCAM-1. This interaction is essential for regulating immune responses and maintaining cell positioning within tissues. The presence of this complex on leukocytes drives their ability to navigate through the vasculature to inflamed areas.

Pathways

Integrin alpha 4 participates in significant signal transduction pathways including the MAPK and PI3K-Akt pathways. These pathways modulate cell survival proliferation and migration. In the MAPK pathway integrin alpha 4 influences cell signaling cascades by interacting with other proteins like TALIN or PAXILLIN which are important for integrin-mediated signal relay. In connection with PI3K-Akt pathway alpha 4 integrins work closely with proteins in regulating cellular adhesion and motility showing a dynamic interplay in immune regulation.

Integrin alpha 4 plays an important role in various immune-related diseases such as multiple sclerosis and Crohn's disease. The protein's participation in leukocyte adhesion and trafficking makes it a target for therapeutic intervention. Natalizumab a monoclonal antibody against alpha 4 integrin showcases the critical link between the protein and disease treatment by blocking leukocyte migration to reduce inflammation. Additionally integrin alpha 4's interaction with proteins like VCAM-1 and VLA-4 highlights its relevance in these autoimmune conditions highlighting its importance in disease pathophysiology.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4 : ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed : 23125415). ITGA4 : ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed : 18635536, PubMed : 25398877). Integrin ITGA4 : ITGB1 represses PRKCA-mediated L-type voltage-gated channel Ca(2+) influx and ROCK-mediated calcium sensitivity in vascular smooth muscle cells via its interaction with SVEP1, thereby inhibiting vasocontraction (PubMed : 35802072).
See full target information ITGA4

Alternative Names

CD49d, CD49D, ITGA4, Integrin alpha-4, CD49 antigen-like family member D, Integrin alpha-IV, VLA-4 subunit alpha

Publications (17)

Recent publications for all applications. Explore the full listand refine your search

Clinical proteomics 21:58 PubMed39385083

2024

Proteomic analysis of plasma exosomes in patients with metastatic colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Zhaoyue Zhong,Jiayin Ji,Hongxia Li,Ling Kang,Haipeng Zhu

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10:e2302910 PubMed37884486

2023

Oral Immunotherapy Reshapes Intestinal Immunosuppression via Metabolic Reprogramming to Enhance Systemic Anti-Tumor Immunity.

Applications

Unspecified application

Species

Unspecified reactive species

Xinran Cao,Yuan Xu,Chen Zhou,Jiawei Huo,Shenge Su,Lei Liu,Ziran Zhu,Lei Li,Wang Jia,Chunru Wang,Mingming Zhen

Nature communications 14:5216 PubMed37626073

2023

A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoying Kang,Yuan Zhang,Jianwen Song,Lu Wang,Wen Li,Ji Qi,Ben Zhong Tang

Frontiers in neurology 14:1113404 PubMed37228411

2023

Increased expression of cell adhesion molecules in myofasciitis.

Applications

Unspecified application

Species

Unspecified reactive species

Xue Ma,Huajie Gao,Li Xu,Zhuajin Bi,Suqiong Ji,Bitao Bu

The Journal of biological chemistry 299:104657 PubMed37001814

2023

miR-147a targets ZEB2 to regulate ox-LDL-induced monocyte adherence to HUVECs, atherosclerotic plaque formation, and stability in atherosclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Fengying Chen,Yuzhen Ning,Jingying Liu,Ming Lian,Juanjuan Wang,Hongwei Dan

Nature communications 13:1768 PubMed35365657

2022

PI3Kγ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation.

Applications

Unspecified application

Species

Unspecified reactive species

Michael C Schmid,Sang Won Kang,Hui Chen,Marc Paradise,Anghesom Ghebremedhin,Megan M Kaneda,Shao-Ming Chin,Anh Do,D Martin Watterson,Judith A Varner

Journal of nanobiotechnology 19:374 PubMed34789284

2021

Macrophage membrane camouflaged reactive oxygen species responsive nanomedicine for efficiently inhibiting the vascular intimal hyperplasia.

Applications

Unspecified application

Species

Unspecified reactive species

Boyan Liu,Wenhua Yan,Li Luo,Shuai Wu,Yi Wang,Yuan Zhong,Dan Tang,Ali Maruf,Meng Yan,Kun Zhang,Xian Qin,Kai Qu,Wei Wu,Guixue Wang

Blood advances 5:3609-3622 PubMed34448828

2021

An irradiated marrow niche reveals a small noncollagenous protein mediator of homing, dermatopontin.

Applications

Unspecified application

Species

Unspecified reactive species

Ashley C Kramer,Yuliana Astuti,Alexis Elfstrum,Michael J Lehrke,Jakub Tolar,Bruce R Blazar,Amanda L Blake,Mandy E Taisto,Justin W Furcich,Erin E Nolan,Wilaiwan W Durose,Beau R Webber,Athena Geisness,David K Wood,Troy C Lund

Journal of cellular and molecular medicine 24:814-829 PubMed31680442

2019

Integrative transcriptomic and proteomic analysis reveals CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma.

Applications

Unspecified application

Species

Unspecified reactive species

Junwei Yan,Xuejiao Yang,Xuefei Jiao,Xian Yang,Mingjin Guo,Yunqing Chen,Lu Zhan,Wenshi Chen

Nature communications 9:1982 PubMed29773794

2018

Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease.

Applications

Unspecified application

Species

Unspecified reactive species

Masayoshi Ohkuro,Jun-Dal Kim,Yoshikazu Kuboi,Yuki Hayashi,Hayase Mizukami,Hiroko Kobayashi-Kuramochi,Kenzo Muramoto,Manabu Shirato,Fumiko Michikawa-Tanaka,Jun Moriya,Teruya Kozaki,Kazuma Takase,Kenichi Chiba,Kishan Lal Agarwala,Takayuki Kimura,Makoto Kotake,Tetsuya Kawahara,Naoki Yoneda,Shinsuke Hirota,Hiroshi Azuma,Nobuko Ozasa-Komura,Yoshiaki Ohashi,Masafumi Muratani,Keiji Kimura,Ieharu Hishinuma,Akiyoshi Fukamizu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com